Illumina In Talks To Buy Cancer Startup Grail

Gene sequencing company Illumina Inc is in late talks to buy cancer testing startup Grail, Bloomberg News reported on Wednesday.

Grail could fetch more than the $6 billion valuation that it had reached from previous fundraisings, the report said, adding the companies could announce a deal as soon as this week.

Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by Inc’s founder Jeff Bezos and billionaire philanthropist Bill Gates.

Illumina is the single largest shareholder in Grail with a 14.6% stake, according to the company’s filing for a US listing last week.

In January, Illumina ended its $1.2 billion deal to buy smaller rival Pacific Biosciences of California Inc, after the US competition watchdog filed a complaint to block the purchase.

Full Content: Bloomberg

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.